Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you consider nivolumab/relatlimab as a salvage therapy option for advanced melanoma patients who progressed on single-agent PD-1 inhibitor?
Related Questions
How do you approach a patient with recurrent chest wall BRAF(+) mutated melanoma who developed multiple metastatic axillary nodes while on immunotherapy, now post axillary dissection for adjuvant radiation?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
How would you approach a patient with desmoplastic melanoma (pT3N0M0) post resection for adjuvant treatment?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
